StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research note released on Monday. The brokerage issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Stock Performance
NASDAQ:ACOR opened at $9.60 on Monday. The company has a quick ratio of 1.65, a current ratio of 1.59 and a debt-to-equity ratio of 3.07. The company has a market cap of $11.92 million, a P/E ratio of -0.56 and a beta of 1.40. Acorda Therapeutics has a fifty-two week low of $8.98 and a fifty-two week high of $24.20. The firm’s 50 day moving average is $11.64 and its two-hundred day moving average is $13.16.
Hedge Funds Weigh In On Acorda Therapeutics
Large investors have recently bought and sold shares of the stock. Deutsche Bank AG purchased a new position in Acorda Therapeutics during the fourth quarter worth approximately $26,000. Prudential Financial Inc. acquired a new stake in shares of Acorda Therapeutics in the second quarter worth $28,000. Geode Capital Management LLC increased its position in shares of Acorda Therapeutics by 44.8% in the fourth quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 20,948 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Acorda Therapeutics in the second quarter worth $68,000. Finally, Susquehanna International Group LLP increased its position in shares of Acorda Therapeutics by 1,759.1% in the first quarter. Susquehanna International Group LLP now owns 218,830 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 207,059 shares in the last quarter.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.
- Five stocks we like better than Acorda Therapeutics
- How to Calculate Inflation Rate
- The most upgraded stocks in November have two things in common
- How to Find Cloud Software Company Stocks to Trade and Invest
- Monday.com rocked earnings like it’s the weekend
- Bank Stocks – Best Bank Stocks to Invest In
- Plan to own one retailer? Make it this one
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.